Ibasunate

Ibasunate (marketed by Elbe Pharma) is a fixed-dose Artemisinin-based Combination Therapy (ACT) antimalarial formulated in soft gelatin capsules. It combines two active pharmaceutical ingredients: dihydroartemisinin (DHA) and piperaquine phosphate.

• Dihydroartemisinin (DHA): The main active metabolite of all artemisinin derivatives. It acts rapidly on blood-stage erythrocytic parasites (trophozoites) by generating intra-parasitic free radicals in the presence of heme iron. This causes fast parasite biomass reduction and rapid fever/symptom clearance within hours.

• Piperaquine Phosphate: A long-acting lipophilic bisquinoline antimalarial derivative. It accumulates within the parasite’s food vacuole and inhibits the polymerization of toxic free heme into inert hemozoin. The accumulation of toxic heme causes membrane destruction, providing extended therapeutic coverage to clear residual parasites and prevent relapse.

The softgel formulation of Ibasunate enhances drug dissolution and bioavailability for smooth gastrointestinal absorption.

Primary Medical Indications

Ibasunate is indicated for adults, adolescents, and children for the treatment of acute parasitic infections:

• Uncomplicated Plasmodium falciparum Malaria: First-line curative treatment for acute, uncomplicated malaria caused by P. falciparum or mixed species infections containing P. falciparum.

• Multi-Drug Resistant Malaria: Highly effective against P. falciparum strains resistant to older antimalarial monotherapies like chloroquine, sulfadoxine-pyrimethamine (Fansidar), or quinine.

• Treatment of Non-falciparum Blood-Stage Parasites: Effective against erythrocytic schizonts of Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae (radical cure for liver hypnozoites in P. vivax and P. ovale requires adjunct therapy with primaquine or tafenoquine).

Key Product Specifications & Dosing Forms

Critical Safety Guidelines & Precautions

• Empty Stomach / Low-Fat Meal Dosing: Piperaquine absorption increases substantially when co-administered with high-fat meals, which can elevate systemic exposure and increase the risk of cardiac side effects. Take Ibasunate on an empty stomach (or with low-fat food).

• First Trimester Contraindication: Ibasunate is contra-indicated / not recommended for use during the first trimester of pregnancy unless advised by a healthcare professional under strict risk-benefit evaluation.

• QTc Prolongation Warning: Piperaquine has the potential to prolong the QTc interval on an ECG. Avoid co-administration with other QT-prolonging drugs (e.g., macrolides, antiarrhythmics, quinine, halofantrine) or in patients with known long QT syndrome.

• Re-Dosing Protocol for Vomiting: If vomiting occurs within 30 to 60 minutes of taking a dose, re-administer a full replacement dose. If persistent vomiting prevents oral retention, switch immediately to parenteral antimalarial therapy (e.g., IV or IM artesunate).

• Not for Severe/Complicated Malaria: Contraindicated for severe or complicated malaria (e.g., cerebral malaria, severe anemia). Severe cases require immediate intravenous antimalarial intervention.

• Prophylaxis Restriction: Ibasunate is strictly a therapeutic curative agent and must never be used for malaria prophylaxis.